title: Thallium-201-chloride and technetium-99m-MIBI SPECT of primary and metastatic lung carcinoma.
abstract: We compared technetium-99m-MIBI (Tc-99m MIBI) with thallium-201-chloride (Tl-201) SPECT imaging in patients with lung carcinoma. In addition, we compared the imaging characteristics of Tl-201 and Tc-99m MIBI after radiation therapy. Thirty-seven patients with primary lung carcinoma were evaluated with SPECT imaging for metastasis to the mediastinal lymph nodes and brain. Patients were imaged with Tl-201 chloride images 10 and 180 min after injection. Patients were also imaged 10 min after injection of Tc-99m MIBI. The sensitivity of Tl-201 SPECT for the primary lesion and brain metastasis was 97.1% and 70.0% respectively at 10 min and 97.1% and 60.0% at 180 min. The sensitivity of Tc-99m MIBI SPECT was 97.1% (for the identification of the primary lesion) and 50.0% (for the detection of brain metastasis) at 10 min. The uptake ratios (count in tumor/count in normal lung or brain) at 10 min on the Tl-201 SPECT and on the Tc-99m MIBI SPECT were not significantly different for the primary tumor or for brain metastasis. The uptake ratios were better for Tc-99m MIBI than for Tl-201 [2.82 vs. 1.99 (p<0.05)] for mediastinal lymph nodes. Decreasing uptake ratios and retention index with both agents after radiation therapy are concordant to the follow-up clinical course. Tc-99m MIBI SPECT is more sensitive in the detection of metastasis to mediastinal lymph nodes than Tl-201 SPECT.
authors.affiliation: Department of Radiology, Okayama University, Medical School, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kashitani
authors.forename: S
authors.initials: S
authors.lastname: Makihara
authors.forename: T
authors.initials: T
authors.lastname: Maeda
authors.forename: R
authors.initials: R
authors.lastname: Eda
authors.forename: H
authors.initials: H
authors.lastname: Takeyama
authors.forename: Y
authors.initials: Y
authors.lastname: Hiraki
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008297:Male; D008482:Mediastinum / Q000000981:diagnostic imaging; D008875:Middle Aged; D012680:Sensitivity and Specificity; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D017256:Technetium Tc 99m Sestamibi; D013794:Thallium Radioisotopes; D013904:Thoracic Vertebrae / Q000000981:diagnostic imaging; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D013794:Thallium Radioisotopes; D017256:Technetium Tc 99m Sestamibi